Literature DB >> 17213021

High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays.

Jane Carr1, Nick P Bown, Marian C Case, Andrew G Hall, John Lunec, Deborah A Tweddle.   

Abstract

Genomic copy number changes are detectable in many malignancies, including neuroblastoma, using techniques such as comparative genomic hybridization (CGH), microsatellite analysis, conventional karyotyping, and fluorescence in situ hybridization (FISH). We report the use of 10K single nucleotide polymorphism (SNP) microarrays to detect copy number changes and allelic imbalance in six neuroblastoma cell lines (IMR32, SHEP, NBL-S, SJNB-1, LS, and SKNBE2c). SNP data were generated using the GeneChip DNA Analysis and GeneChip chromosome copy number software (Affymetrix). SNP arrays confirmed the presence of all previously reported cytogenetic abnormalities in the cell lines, including chromosome 1p deletion, MYCN amplification, gain of 17q and 11q, and 14q deletions. In addition, the SNP arrays revealed several chromosome gains and losses not detected by CGH or karyotyping; these included gain of 8q21.1 approximately 24.3 and gain of chromosome 12 in IMR-32 cells; loss at 4p15.3 approximately 16.1 and loss at 16p12.3 approximately 13.2, 11q loss with loss of heterozygosity (LOH) at 11q14.3 approximately 23.3 in SJNB-1 cells; and loss at 8p21.2 approximately 23.3 and 9p21.3 approximately 22.1 with corresponding LOH in SHEP cells. The SNP arrays refined the mapping of the 2p amplicons in LS, BE2c, and IMR-32 cell lines, the 12q amplicon in LS cells, and also identified an 11q13 amplicon in LS cells. There was good concordance among SNP arrays, CGH, and karyotyping. SNP array analysis is a powerful tool for the detection of allelic imbalance in neuroblastoma and also allows identification of LOH without changes in copy number (uniparental disomy).

Entities:  

Mesh:

Year:  2007        PMID: 17213021     DOI: 10.1016/j.cancergencyto.2006.08.012

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  11 in total

1.  High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.

Authors:  Jane Carr-Wilkinson; Kieran O'Toole; Katrina M Wood; Christine C Challen; Angela G Baker; Julian R Board; Laura Evans; Michael Cole; Nai-Kong V Cheung; Joachim Boos; Gabriele Köhler; Ivo Leuschner; Andrew D J Pearson; John Lunec; Deborah A Tweddle
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

Review 2.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

3.  Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma.

Authors:  Eva Villamón; Marta Piqueras; Carlos Mackintosh; Javier Alonso; Enrique de Alava; Samuel Navarro; Rosa Noguera
Journal:  Virchows Arch       Date:  2008-06-24       Impact factor: 4.064

4.  Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.

Authors:  Cihan Cetinkaya; Tommy Martinsson; Johanna Sandgren; Catarina Träger; Per Kogner; Jan Dumanski; Teresita Díaz de Ståhl; Fredrik Hedborg
Journal:  BMC Cancer       Date:  2013-05-09       Impact factor: 4.430

5.  Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors.

Authors:  Hanna Kryh; Helena Carén; Jennie Erichsen; Rose-Marie Sjöberg; Jonas Abrahamsson; Per Kogner; Tommy Martinsson
Journal:  BMC Genomics       Date:  2011-09-07       Impact factor: 3.969

6.  High-resolution array CGH profiling identifies Na/K transporting ATPase interacting 2 (NKAIN2) as a predisposing candidate gene in neuroblastoma.

Authors:  Paolo Romania; Aurora Castellano; Cecilia Surace; Arianna Citti; Maria Antonietta De Ioris; Pietro Sirleto; Marilena De Mariano; Luca Longo; Renata Boldrini; Adriano Angioni; Franco Locatelli; Doriana Fruci
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

7.  Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.

Authors:  Yanna Cao; Yan Jin; Jinpu Yu; Jingfu Wang; Yanli Qiu; Xiaofeng Duan; Yingnan Ye; Yanan Cheng; Li Dong; Xiaolong Feng; Daowei Wang; Zhongyuan Li; Xiangdong Tian; Huijuan Wang; Jie Yan; Qiang Zhao
Journal:  Oncotarget       Date:  2017-07-25

8.  Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.

Authors:  Jo Lynne Harenza; Maura A Diamond; Rebecca N Adams; Michael M Song; Heather L Davidson; Lori S Hart; Maiah H Dent; Paolo Fortina; C Patrick Reynolds; John M Maris
Journal:  Sci Data       Date:  2017-03-28       Impact factor: 6.444

9.  Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN.

Authors:  Anne Guimier; Sandrine Ferrand; Gaëlle Pierron; Jérôme Couturier; Isabelle Janoueix-Lerosey; Valérie Combaret; Véronique Mosseri; Estelle Thebaud; Marion Gambart; Dominique Plantaz; Aurélien Marabelle; Carole Coze; Xavier Rialland; Sylvie Fasola; Eve Lapouble; Paul Fréneaux; Michel Peuchmaur; Jean Michon; Olivier Delattre; Gudrun Schleiermacher
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

10.  Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours.

Authors:  Noémie Braekeveldt; Caroline Wigerup; David Gisselsson; Sofie Mohlin; My Merselius; Siv Beckman; Tord Jonson; Anna Börjesson; Torbjörn Backman; Irene Tadeo; Ana P Berbegall; Ingrid Ora; Samuel Navarro; Rosa Noguera; Sven Påhlman; Daniel Bexell
Journal:  Int J Cancer       Date:  2014-10-07       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.